Literature DB >> 8869035

Detection of IL-1 alpha, IL-1 beta and IL-1 receptor antagonist in blister fluid of bullous pemphigoid.

E Schmidt1, A Mittnacht, H Schömig, R Dummer, E B Bröcker, D Zillikens.   

Abstract

Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease. In addition to autoantibodies, complement activation and inflammatory cells are necessary for lesion formation. In this study, we investigated the potential involvement of IL-1, secreted by various inflammatory and non-inflammatory cells, in BP lesions. We determined IL-1 alpha IL-1 beta and IL-1 receptor antagonist in both blister fluid and concurrent serum samples of 10 BP patients by ELISAs. For comparison, we assayed experimentally generated suction blisters from 10 healthy volunteers. IL-1 beta levels were significantly elevated in BP blisters, whereas levels of IL-1 alpha were decreased relative to those in controls. In concurrent serum samples, no IL-1 alpha or IL-1 beta were detected in patients or controls. Levels of IL-1 receptor antagonist were significantly higher in BP blisters in relation to both concurrent sera and suction blisters. Our data indicate the release of IL-1 beta, IL-1 receptor antagonist, and to a lesser extent, of IL-1 alpha, at the site of blister formation in BP and support the notion that cell-mediated immune mechanisms may contribute to blister formation in this disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8869035     DOI: 10.1016/0923-1811(95)00435-1

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  9 in total

1.  A gene network bioinformatics analysis for pemphigoid autoimmune blistering diseases.

Authors:  Antonio Barone; Paolo Toti; Maria Rita Giuca; Giacomo Derchi; Ugo Covani
Journal:  Clin Oral Investig       Date:  2014-11-08       Impact factor: 3.573

Review 2.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis.

Authors:  K Juczynska; A Wozniacka; E Waszczykowska; M Danilewicz; M Wagrowska-Danilewicz; J Wieczfinska; R Pawliczak; A Zebrowska
Journal:  Mediators Inflamm       Date:  2017-10-24       Impact factor: 4.711

4.  Proinflammatory Cytokine Gene Polymorphisms in Bullous Pemphigoid.

Authors:  Pardis-Sadat Tabatabaei-Panah; Hamideh Moravvej; Zahra Sadaf; Hadis Babaei; Maryam Geranmayeh; Sedigheh Hajmanouchehri; Ahmad Karimi; Fatemeh Sajjadi; Fereshteh Arghand; Ralf J Ludwig; Mareike Witte; Reza Akbarzadeh
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

Review 5.  Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.

Authors:  Kata P Szilveszter; Tamás Németh; Attila Mócsai
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

6.  Innate immune activation as cofactor in pemphigus disease manifestation.

Authors:  Ramona A Eichkorn; Morna F Schmidt; Elias Walter; Michael Hertl; Jens Malte Baron; Jens Waschke; Amir S Yazdi
Journal:  Front Immunol       Date:  2022-07-19       Impact factor: 8.786

Review 7.  Investigation of comorbid autoimmune diseases in women with autoimmune bullous diseases: An interplay of autoimmunity and practical implications.

Authors:  Meropi Karakioulaki; Dedee F Murrell; Aikaterini Kyriakou; Aikaterini Patsatsi
Journal:  Int J Womens Dermatol       Date:  2022-10-07

Review 8.  Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid.

Authors:  Lisa Leighty; Ning Li; Luis A Diaz; Zhi Liu
Journal:  Arch Dermatol Res       Date:  2007-09-19       Impact factor: 3.017

9.  IL-23/IL-17 Axis Activates IL-1β-Associated Inflammasome in Macrophages and Generates an Auto-Inflammatory Response in a Subgroup of Patients With Bullous Pemphigoid.

Authors:  Sébastien Le Jan; Céline Muller; Julie Plee; Anne Durlach; Philippe Bernard; Frank Antonicelli
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.